Form 4: Halozyme CEO Exercises Options, Sells Shares

Halozyme Therapeutics CEO Helen Torley exercised stock options and sold shares totaling 60,000 units over three days in August 2025, realizing significant gains.

Summary

• Helen Torley, President and CEO, and a Director of Halozyme Therapeutics, Inc. (HALO), reported transactions involving the exercise of stock options and subsequent sale of common stock.
• The transactions occurred on August 11, 12, and 13, 2025, and were executed pursuant to a Rule 10b5-1 trading plan adopted on March 21, 2025.
• On each of the three days, Ms. Torley exercised options to acquire 20,000 shares of common stock at an exercise price of $8.11 per share, totaling 60,000 shares acquired.
• Concurrently, on each of the three days, she sold 20,000 shares of common stock, totaling 60,000 shares disposed.
• The sales on August 11, 2025, were at weighted average prices of $63.008 (18,717 shares) and $63.598 (1,283 shares).
• The sales on August 12, 2025, were at weighted average prices of $63.242 (13,042 shares) and $64.001 (6,958 shares).
• The sales on August 13, 2025, were at weighted average prices of $64.145 (14,948 shares) and $64.828 (5,052 shares).
• The options exercised had a ten-year term expiring in February 2026, indicating they were nearing their expiration date.
• Following these transactions, Ms. Torley's direct beneficial ownership of common stock is 733,719 shares, and her derivative holdings (options) decreased to 196,569.

Sentiment

Score: 7

Explanation: The CEO realized substantial gains from exercising expiring options and selling shares under a pre-planned trading arrangement. While insider selling can sometimes be viewed negatively, the pre-planned nature and the context of expiring options mitigate significant negative sentiment.

Positives

• The CEO realized substantial personal gains by exercising stock options at a low price ($8.11) and selling the shares at significantly higher market prices (ranging from $62.54 to $64.96).
• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, which demonstrates transparency and reduces concerns about opportunistic insider selling.

Negatives

• The sale of 60,000 shares by a key executive, even if pre-planned, represents a reduction in direct insider ownership, which some investors might view with slight caution.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders may note the CEO's decision to realize gains from her stock options, which is a common practice for executives, especially when options are nearing expiration.
• The pre-planned nature of the sales (10b5-1 plan) suggests a structured approach to managing personal holdings rather than a reaction to immediate company performance concerns.

Key Dates

Recommendation

The filing details pre-planned insider sales by the CEO, Helen Torley, involving the exercise of expiring stock options and subsequent sale of shares. While the CEO realized significant personal gains, these transactions were executed under a Rule 10b5-1 plan, which reduces the implication of discretionary selling. The filing does not provide new information regarding the company's operational performance or strategic direction that would warrant a change in investment thesis based solely on this report.

Keywords

Halozyme Therapeutics, HALO, SEC Form 4, Insider Trading, Stock Options, Share Sale, CEO, Helen Torley, 10b5-1 Plan